Loading…

Y-26763 protects the canine heart from a stunning injury through opening of the KATP channels

The present study describes the protective effects of the ATP-sensitive K+ (KATP) channel opener Y-26763 ((-)-(3S,4R-4-(N-acetyl-N-hydroxyamino)-6-cyano-3,4-dihydro-2,2-dimethyl -2H-1-benzopyran-3-ol), on a model of reversible ischemia/reperfusion injury ('stunned' myocardium). Stunning wa...

Full description

Saved in:
Bibliographic Details
Published in:European journal of pharmacology 1997-04, Vol.323 (2-3), p.197-204
Main Authors: FUKUNARI, A, MIYAI, H, SHINAGAWA, K, KAWAHARA, K, NAKAJIMA, T
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c1809-c3a792b341525c926b7beadf7ff90cc73d2cd96855b92028f0dd5e5446cb9cfe3
cites cdi_FETCH-LOGICAL-c1809-c3a792b341525c926b7beadf7ff90cc73d2cd96855b92028f0dd5e5446cb9cfe3
container_end_page 204
container_issue 2-3
container_start_page 197
container_title European journal of pharmacology
container_volume 323
creator FUKUNARI, A
MIYAI, H
SHINAGAWA, K
KAWAHARA, K
NAKAJIMA, T
description The present study describes the protective effects of the ATP-sensitive K+ (KATP) channel opener Y-26763 ((-)-(3S,4R-4-(N-acetyl-N-hydroxyamino)-6-cyano-3,4-dihydro-2,2-dimethyl -2H-1-benzopyran-3-ol), on a model of reversible ischemia/reperfusion injury ('stunned' myocardium). Stunning was caused by 10-min occlusion of the left circumflex coronary artery followed by 3-h reperfusion in pentobarbital anesthetized beagle dogs. This procedure reduced by over 80% myocardial segment function measured by sonomicrometry in control preparations. Y-26763, administered 10 min before the left circumflex coronary artery occlusion, at a dose (3 micrograms/kg, i.v.) lacking significant systemic hemodynamic effects, produced a rapid and marked (80%) recovery of the shortening of the ischemic segment. By contrast, nifedipine (1 microgram/kg plus 0.2 microgram/kg per min, i.v.) did not ameliorate postischemic function. Glibenclamide, administered before Y-26763 at a dose (0.3 mg/kg, i.v.) that did not affect adversely hemodynamics and stunning injury negated the beneficial action of Y-26763. However, glibenclamide failed to do so when administered 2 min before starting reperfusion. The ischemia/reperfusion areas, which were measured by digital image analysis with NIH image software, were similar among experimental groups. Overall, these results indicate that Y-26763 protects the canine myocardium from reversible ischemia/reperfusion injury, probably through activation of myocardial KATP channels which appear to be involved in affording protection during the ischemic insult and not at the reperfusion.
doi_str_mv 10.1016/S0014-2999(97)00035-6
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78967314</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78967314</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1809-c3a792b341525c926b7beadf7ff90cc73d2cd96855b92028f0dd5e5446cb9cfe3</originalsourceid><addsrcrecordid>eNo9kE1LAzEQhoMotVZ_QiEHET2s5mOT7Byl-IUFBevBg4RsNmm3bHdrsnvov3f7QU8DM887wzwIjSm5p4TKhy9CaJowALgFdUcI4SKRJ2hIMwUJUZSdouEROUcXMS57SAATAzQAyrKMwxD9_iRMKsnxOjSts23E7cJha-qydnjhTGixD80KGxzbru67c1zWyy5sei403XyBm7XbtRu_i74_zj6xXZi6dlW8RGfeVNFdHeoIfT8_zSavyfTj5W3yOE0szQgklhsFLOcpFUxYYDJXuTOFV94DsVbxgtkCZCZEDoywzJOiEE6kqbQ5WO_4CN3s9_Zf_HUutnpVRuuqytSu6aJWGUjFadqDYg_a0MQYnNfrUK5M2GhK9Far3mnVW2calN5p1bLPjQ8HunzlimPq4LGfXx_mJlpT-WBqW8YjxiRXLFP8Hwqrf0o</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78967314</pqid></control><display><type>article</type><title>Y-26763 protects the canine heart from a stunning injury through opening of the KATP channels</title><source>Elsevier</source><creator>FUKUNARI, A ; MIYAI, H ; SHINAGAWA, K ; KAWAHARA, K ; NAKAJIMA, T</creator><creatorcontrib>FUKUNARI, A ; MIYAI, H ; SHINAGAWA, K ; KAWAHARA, K ; NAKAJIMA, T</creatorcontrib><description>The present study describes the protective effects of the ATP-sensitive K+ (KATP) channel opener Y-26763 ((-)-(3S,4R-4-(N-acetyl-N-hydroxyamino)-6-cyano-3,4-dihydro-2,2-dimethyl -2H-1-benzopyran-3-ol), on a model of reversible ischemia/reperfusion injury ('stunned' myocardium). Stunning was caused by 10-min occlusion of the left circumflex coronary artery followed by 3-h reperfusion in pentobarbital anesthetized beagle dogs. This procedure reduced by over 80% myocardial segment function measured by sonomicrometry in control preparations. Y-26763, administered 10 min before the left circumflex coronary artery occlusion, at a dose (3 micrograms/kg, i.v.) lacking significant systemic hemodynamic effects, produced a rapid and marked (80%) recovery of the shortening of the ischemic segment. By contrast, nifedipine (1 microgram/kg plus 0.2 microgram/kg per min, i.v.) did not ameliorate postischemic function. Glibenclamide, administered before Y-26763 at a dose (0.3 mg/kg, i.v.) that did not affect adversely hemodynamics and stunning injury negated the beneficial action of Y-26763. However, glibenclamide failed to do so when administered 2 min before starting reperfusion. The ischemia/reperfusion areas, which were measured by digital image analysis with NIH image software, were similar among experimental groups. Overall, these results indicate that Y-26763 protects the canine myocardium from reversible ischemia/reperfusion injury, probably through activation of myocardial KATP channels which appear to be involved in affording protection during the ischemic insult and not at the reperfusion.</description><identifier>ISSN: 0014-2999</identifier><identifier>EISSN: 1879-0712</identifier><identifier>DOI: 10.1016/S0014-2999(97)00035-6</identifier><identifier>PMID: 9128839</identifier><identifier>CODEN: EJPHAZ</identifier><language>eng</language><publisher>Amsterdam: Elsevier</publisher><subject>Adenosine Triphosphate - metabolism ; Animals ; Antihypertensive Agents - pharmacology ; Benzopyrans - pharmacology ; Biological and medical sciences ; Calcium Channel Blockers - pharmacology ; Cardiovascular system ; Dogs ; Female ; Glyburide - pharmacology ; Hemodynamics - drug effects ; Male ; Medical sciences ; Miscellaneous ; Myocardial Stunning - physiopathology ; Myocardial Stunning - prevention &amp; control ; Nifedipine - pharmacology ; Pharmacology. Drug treatments ; Potassium Channels - drug effects</subject><ispartof>European journal of pharmacology, 1997-04, Vol.323 (2-3), p.197-204</ispartof><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1809-c3a792b341525c926b7beadf7ff90cc73d2cd96855b92028f0dd5e5446cb9cfe3</citedby><cites>FETCH-LOGICAL-c1809-c3a792b341525c926b7beadf7ff90cc73d2cd96855b92028f0dd5e5446cb9cfe3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2637287$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9128839$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>FUKUNARI, A</creatorcontrib><creatorcontrib>MIYAI, H</creatorcontrib><creatorcontrib>SHINAGAWA, K</creatorcontrib><creatorcontrib>KAWAHARA, K</creatorcontrib><creatorcontrib>NAKAJIMA, T</creatorcontrib><title>Y-26763 protects the canine heart from a stunning injury through opening of the KATP channels</title><title>European journal of pharmacology</title><addtitle>Eur J Pharmacol</addtitle><description>The present study describes the protective effects of the ATP-sensitive K+ (KATP) channel opener Y-26763 ((-)-(3S,4R-4-(N-acetyl-N-hydroxyamino)-6-cyano-3,4-dihydro-2,2-dimethyl -2H-1-benzopyran-3-ol), on a model of reversible ischemia/reperfusion injury ('stunned' myocardium). Stunning was caused by 10-min occlusion of the left circumflex coronary artery followed by 3-h reperfusion in pentobarbital anesthetized beagle dogs. This procedure reduced by over 80% myocardial segment function measured by sonomicrometry in control preparations. Y-26763, administered 10 min before the left circumflex coronary artery occlusion, at a dose (3 micrograms/kg, i.v.) lacking significant systemic hemodynamic effects, produced a rapid and marked (80%) recovery of the shortening of the ischemic segment. By contrast, nifedipine (1 microgram/kg plus 0.2 microgram/kg per min, i.v.) did not ameliorate postischemic function. Glibenclamide, administered before Y-26763 at a dose (0.3 mg/kg, i.v.) that did not affect adversely hemodynamics and stunning injury negated the beneficial action of Y-26763. However, glibenclamide failed to do so when administered 2 min before starting reperfusion. The ischemia/reperfusion areas, which were measured by digital image analysis with NIH image software, were similar among experimental groups. Overall, these results indicate that Y-26763 protects the canine myocardium from reversible ischemia/reperfusion injury, probably through activation of myocardial KATP channels which appear to be involved in affording protection during the ischemic insult and not at the reperfusion.</description><subject>Adenosine Triphosphate - metabolism</subject><subject>Animals</subject><subject>Antihypertensive Agents - pharmacology</subject><subject>Benzopyrans - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Calcium Channel Blockers - pharmacology</subject><subject>Cardiovascular system</subject><subject>Dogs</subject><subject>Female</subject><subject>Glyburide - pharmacology</subject><subject>Hemodynamics - drug effects</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Miscellaneous</subject><subject>Myocardial Stunning - physiopathology</subject><subject>Myocardial Stunning - prevention &amp; control</subject><subject>Nifedipine - pharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Potassium Channels - drug effects</subject><issn>0014-2999</issn><issn>1879-0712</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><recordid>eNo9kE1LAzEQhoMotVZ_QiEHET2s5mOT7Byl-IUFBevBg4RsNmm3bHdrsnvov3f7QU8DM887wzwIjSm5p4TKhy9CaJowALgFdUcI4SKRJ2hIMwUJUZSdouEROUcXMS57SAATAzQAyrKMwxD9_iRMKsnxOjSts23E7cJha-qydnjhTGixD80KGxzbru67c1zWyy5sei403XyBm7XbtRu_i74_zj6xXZi6dlW8RGfeVNFdHeoIfT8_zSavyfTj5W3yOE0szQgklhsFLOcpFUxYYDJXuTOFV94DsVbxgtkCZCZEDoywzJOiEE6kqbQ5WO_4CN3s9_Zf_HUutnpVRuuqytSu6aJWGUjFadqDYg_a0MQYnNfrUK5M2GhK9Far3mnVW2calN5p1bLPjQ8HunzlimPq4LGfXx_mJlpT-WBqW8YjxiRXLFP8Hwqrf0o</recordid><startdate>19970404</startdate><enddate>19970404</enddate><creator>FUKUNARI, A</creator><creator>MIYAI, H</creator><creator>SHINAGAWA, K</creator><creator>KAWAHARA, K</creator><creator>NAKAJIMA, T</creator><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19970404</creationdate><title>Y-26763 protects the canine heart from a stunning injury through opening of the KATP channels</title><author>FUKUNARI, A ; MIYAI, H ; SHINAGAWA, K ; KAWAHARA, K ; NAKAJIMA, T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1809-c3a792b341525c926b7beadf7ff90cc73d2cd96855b92028f0dd5e5446cb9cfe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Adenosine Triphosphate - metabolism</topic><topic>Animals</topic><topic>Antihypertensive Agents - pharmacology</topic><topic>Benzopyrans - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Calcium Channel Blockers - pharmacology</topic><topic>Cardiovascular system</topic><topic>Dogs</topic><topic>Female</topic><topic>Glyburide - pharmacology</topic><topic>Hemodynamics - drug effects</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Miscellaneous</topic><topic>Myocardial Stunning - physiopathology</topic><topic>Myocardial Stunning - prevention &amp; control</topic><topic>Nifedipine - pharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Potassium Channels - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>FUKUNARI, A</creatorcontrib><creatorcontrib>MIYAI, H</creatorcontrib><creatorcontrib>SHINAGAWA, K</creatorcontrib><creatorcontrib>KAWAHARA, K</creatorcontrib><creatorcontrib>NAKAJIMA, T</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>FUKUNARI, A</au><au>MIYAI, H</au><au>SHINAGAWA, K</au><au>KAWAHARA, K</au><au>NAKAJIMA, T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Y-26763 protects the canine heart from a stunning injury through opening of the KATP channels</atitle><jtitle>European journal of pharmacology</jtitle><addtitle>Eur J Pharmacol</addtitle><date>1997-04-04</date><risdate>1997</risdate><volume>323</volume><issue>2-3</issue><spage>197</spage><epage>204</epage><pages>197-204</pages><issn>0014-2999</issn><eissn>1879-0712</eissn><coden>EJPHAZ</coden><abstract>The present study describes the protective effects of the ATP-sensitive K+ (KATP) channel opener Y-26763 ((-)-(3S,4R-4-(N-acetyl-N-hydroxyamino)-6-cyano-3,4-dihydro-2,2-dimethyl -2H-1-benzopyran-3-ol), on a model of reversible ischemia/reperfusion injury ('stunned' myocardium). Stunning was caused by 10-min occlusion of the left circumflex coronary artery followed by 3-h reperfusion in pentobarbital anesthetized beagle dogs. This procedure reduced by over 80% myocardial segment function measured by sonomicrometry in control preparations. Y-26763, administered 10 min before the left circumflex coronary artery occlusion, at a dose (3 micrograms/kg, i.v.) lacking significant systemic hemodynamic effects, produced a rapid and marked (80%) recovery of the shortening of the ischemic segment. By contrast, nifedipine (1 microgram/kg plus 0.2 microgram/kg per min, i.v.) did not ameliorate postischemic function. Glibenclamide, administered before Y-26763 at a dose (0.3 mg/kg, i.v.) that did not affect adversely hemodynamics and stunning injury negated the beneficial action of Y-26763. However, glibenclamide failed to do so when administered 2 min before starting reperfusion. The ischemia/reperfusion areas, which were measured by digital image analysis with NIH image software, were similar among experimental groups. Overall, these results indicate that Y-26763 protects the canine myocardium from reversible ischemia/reperfusion injury, probably through activation of myocardial KATP channels which appear to be involved in affording protection during the ischemic insult and not at the reperfusion.</abstract><cop>Amsterdam</cop><pub>Elsevier</pub><pmid>9128839</pmid><doi>10.1016/S0014-2999(97)00035-6</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0014-2999
ispartof European journal of pharmacology, 1997-04, Vol.323 (2-3), p.197-204
issn 0014-2999
1879-0712
language eng
recordid cdi_proquest_miscellaneous_78967314
source Elsevier
subjects Adenosine Triphosphate - metabolism
Animals
Antihypertensive Agents - pharmacology
Benzopyrans - pharmacology
Biological and medical sciences
Calcium Channel Blockers - pharmacology
Cardiovascular system
Dogs
Female
Glyburide - pharmacology
Hemodynamics - drug effects
Male
Medical sciences
Miscellaneous
Myocardial Stunning - physiopathology
Myocardial Stunning - prevention & control
Nifedipine - pharmacology
Pharmacology. Drug treatments
Potassium Channels - drug effects
title Y-26763 protects the canine heart from a stunning injury through opening of the KATP channels
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T02%3A30%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Y-26763%20protects%20the%20canine%20heart%20from%20a%20stunning%20injury%20through%20opening%20of%20the%20KATP%20channels&rft.jtitle=European%20journal%20of%20pharmacology&rft.au=FUKUNARI,%20A&rft.date=1997-04-04&rft.volume=323&rft.issue=2-3&rft.spage=197&rft.epage=204&rft.pages=197-204&rft.issn=0014-2999&rft.eissn=1879-0712&rft.coden=EJPHAZ&rft_id=info:doi/10.1016/S0014-2999(97)00035-6&rft_dat=%3Cproquest_cross%3E78967314%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1809-c3a792b341525c926b7beadf7ff90cc73d2cd96855b92028f0dd5e5446cb9cfe3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=78967314&rft_id=info:pmid/9128839&rfr_iscdi=true